
OUR PIPELINE
At Cell4Cure, we develop personalized cell therapies designed to cure or prevent conditions by mimicking the body’s natural process of achieving antigen-specific tolerance. Leveraging our proprietary technology platform, we have achieved significant development milestones, including EMA approval for a clinical trial and the establishment of a robust GMP manufacturing process, supported by $30 million in R&D investments.
​
Our initial focus is on addressing Anti-Drug Antibodies (ADAs), which can diminish or completely inhibit the therapeutic effects of life-saving biological treatments. These biological drugs, commonly used in rheumatology and oncology—such as checkpoint inhibitors and TNF-α inhibitors—are often impacted by ADAs.
For our first clinical program, "Recre8," we have prioritized treating Hemophilia A patients who have developed ADAs, or "inhibitors," against factor VIII. This patient group was selected based on key factors:
​
-
Availability of GMP-manufactured antigen (recombinant FVIII),
-
Accessibility of eligible patients already under physician care,
-
Validated methods for measuring neutralizing antibodies (NAbs),
-
A significant unmet medical need within this population.
​
In parallel, we plan to collaborate with pharmaceutical companies whose biological therapies are affected by ADAs, which can severely reduce clinical efficacy or introduce adverse side effects. Examples of such therapies include blockbuster drugs like Keytruda®, Yervoy®, Opdivo®, and Humira®.
Beyond ADAs, Cell4Cure’s patented technology platform holds the potential to expand into treating autoimmune diseases and addressing challenges in transplant immunology. This positions us at the forefront of personalized medicine and immune tolerance research, paving the way for transformative advancements in patient care.

CLINICAL STUDY - TOLER 8
